SpotitEarly Knowledge Center

The global cancer diagnostics market is on track to reach $155 billion by 2030, with multi-cancer early detection (MCED) growing even faster. This article looks at the scale of the market, the gaps in current screening, the recent enactment of H.R. 842 into Medicare law, and the dynamics driving growth. It also positions SpotitEarly's breath-based pre-screening approach within an expanding category that is shifting healthcare from late treatment toward earlier detection.

SpotitEarly plans to scale its technology to meet a growing global user base through the modular design of its LUCID platform. The approach combines automation, standardized VOC analysis, and patient-friendly sample collection. With adaptability for diverse environments and a focus on accessibility, SpotitEarly ensures consistent quality, efficiency, and reach in expanding cancer detection worldwide.

The recent Rainbow clinical study, published in Nature Scientific Reports, showcases SpotitEarly’s extraordinary success. It shows SpotitEarly is able to detect cancer at early stages with sensitivity rates exceeding 90% for multiple cancers, including those with no standard screening options available today. This breakthrough positions SpotitEarly as a world leader in early disease detection technology.

As SpotitEarly’s COO and co-founder, Udi Bobrovsky oversees the operational and strategic direction of the company’s early cancer detection platform. In this interview, he shares how his background in tech entrepreneurship and digital health drives the company’s mission, his approach to scaling a hybrid canine-AI screening system, and why he believes innovation and collaboration are key to transforming cancer detection globally.

At the heart of SpotitEarly’s innovation are its partnerships with leading hospitals and research institutions worldwide. This post explains how these clinical collaborations validate the accuracy of its breath-based screening method, integrate with existing protocols, and enhance early cancer detection efforts. Learn how SpotitEarly’s platform works alongside—not against—current standards for better, non-invasive diagnostics.

SpotitEarly’s mission is to bring accurate, non-invasive cancer screening to people across the globe. In this post, we explore how our unique bio-AI hybrid approach, combining breath analysis with trained canine detection and artificial intelligence, is making early detection accessible, scalable, and effective. Learn how we’re fighting cancer by reaching more people, earlier, and saving lives.